Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
FINAL OVERALL SURVIVAL AND LONG-TERM SAFETY IN THE ENGOT-OV16/NOVA PHASE 3 TRIAL OF NIRAPARIB IN PATIENTS WITH RECURRENT OVARIAN CANCER
FINAL OVERALL SURVIVAL AND LONG-TERM SAFETY IN THE ENGOT-OV16/NOVA PHASE 3 TRIAL OF NIRAPARIB IN PATIENTS WITH RECURRENT OVARIAN CANCER Marme, F., Matulonis, U., Herrstedt, J., Oza, A., Mahner, S., Redondo, A., Berton, D., Berek, J. S., Haslund, C. A., Gonzalez-Martin, A., Becourt, S., Tinker, A. V., Ledermann, J., Benigno, B., Lindahl, G., Colombo, N., Malinowska, I. A., Liu, W., Schmitz, M. A., Monk, B. J., Mirza, M. R. INT INST ANTICANCER RESEARCH. 2023: 3363-3364View details for Web of Science ID 001072909600054